Levosimendan in End-Stage Heart Failure
نویسندگان
چکیده
منابع مشابه
Preliminary clinical experience with the repetitive administration of levosimendan in patients with end-stage heart failure.
We present our preliminary clinical experience with the initial and repetitive administration of the novel inotropic agent levosimendan in a cohort of 20 patients with end-stage heart failure who were acutely decompensated or whose symptoms were refractory to the usual pharmacological treatments thus necessitating hospitalization. Repetitive levosimendan infusions were administered to 9 patient...
متن کاملEnd-stage chronic heart failure.
Congestive heart failure (CHF) has kept its progressive nature despite significant advances in therapy. With more advanced disease, medical therapy is broadened. Even so, some patients remain severely symptomatic. However, before additional action is taken, it should be regarded if therapy really fails. Often, therapy is not increased sufficiently because of assumed rather than actual intolerab...
متن کاملDilemmas in end-stage heart failure
Heart failure (HF), a complex clinical syndrome due to structural or functional disorder of the heart, is a major global health issue, with a prevalence of over 5.8 million in the USA alone, and over 23 million worldwide. As a leading cause of hospitalizations among patients aged 65 years or older, HF is a major consumer of healthcare resources, creating a substantial strain on the healthcare s...
متن کاملAdvanced Therapies For End-Stage Heart Failure
Management of the advanced heart failure patient can be complex. Therapies include cardiac transplantation and mechanical circulatory support, as well inotropic agents for the short-term. Despite a growing armamentarium of resources, the clinician must carefully weigh the risks and benefits of each therapy to develop an optimal treatment strategy. While cardiac transplantation remains the only ...
متن کاملEnd Stage Heart Failure – Transplantation or Lvad?
Heart failure is a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill or eject blood. According to the data from the International Society for Heart and Lung Transplantation registry, the half-life of patient survival after heart transplantation has progressively improved from 8.9 years in 1982 to a proj...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JACC: Heart Failure
سال: 2013
ISSN: 2213-1779
DOI: 10.1016/j.jchf.2013.04.006